Q-omics provides the consensus-scored HNRNPCL2 profile across patient tissues and cancer cell-line models. HNRNPCL2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, HNRNPCL2 is differentially expressed in 8, with the highest sampling consensus in LUSC. Additionally, HNRNPCL2 RNA expression shows 5,768 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight PAAD, LUSC, and STAD as cancer lineages where HNRNPCL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPCL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPCL2 survival associations across molecular data types. HNRNPCL2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPCL2 RNA expression–survival associations across cancer types. High HNRNPCL2 expression shows unfavorable associations in PAAD, HNSC, STAD and UVM, but favorable associations in BLCA and CESC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for HNRNPCL2 RNA expression.
This table summarizes HNRNPCL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPCL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPCL2 shows lower tumor expression in PAAD and READ and higher tumor expression in LUSC, LIHC, THCA and BLCA. The LUSC box plot shows higher HNRNPCL2 RNA expression in tumor versus normal tissue (log2 FC = +0.028, t-test p = .001).
This table shows molecular features associated with HNRNPCL2 in patient tissues and cancer cell lines. In patient samples, HNRNPCL2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPCL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
